Drug Profile


Alternative Names: AER-001; Aerovant; BAY-16-9996; non-PEGylated AER-001; non-PEGylated pitrakinra

Latest Information Update: 19 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer Aerovance; Bayer
  • Class Antiasthmatics
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute asthma; Allergic asthma; Asthma; Atopic dermatitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 22 Sep 2010 Efficacy and adverse events data from a phase II trial in Asthma presented at the 20th Annual Congress of the European Respiratory Society (ERS-2010)
  • 08 Jun 2010 Aerovance shares phase IIb data with potential partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top